Dac51 is a potent FTO inhibitor with an IC50 of 0.4 μM for inhibiting FTO demethylation.
Dac51 can serve as a potent FTO inhibitor to dampen the glycolytic capacity of tumor cells by inhibiting FTO-mediated demethylation on transcripts including Jun and Cebpb.[1]
Dac51, a FTO inhibitor, delivers strong T cell-mediated antitumor effects and prevents tumor recurrence via increasesing CD8+ T cell in?ltration in tumors, in multiple vivo cancer models.[1]
[1] Yi Liu, et al. Cell Metab. 2021 Jun 1;33(6):1221-1233.e11.